344 related articles for article (PubMed ID: 34185336)
1. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
Herzog Tzarfati K; Gutwein O; Apel A; Rahimi-Levene N; Sadovnik M; Harel L; Benveniste-Levkovitz P; Bar Chaim A; Koren-Michowitz M
Am J Hematol; 2021 Oct; 96(10):1195-1203. PubMed ID: 34185336
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
3. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
[TBL] [Abstract][Full Text] [Related]
4. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.
Morawska M
Eur J Haematol; 2022 Feb; 108(2):91-98. PubMed ID: 34717004
[TBL] [Abstract][Full Text] [Related]
5. Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study.
Hillyer A; Quint A; Ghassemian A; Joh-Carnella N; Knauer MJ; Dawd D; Lazo-Langner A; Mangel J; Lam S; Abdoh H; Xenocostas A; Deotare U; Saini L; Foster C; Louzada M; Ho J; Chin-Yee I; Phua CW
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):305-315. PubMed ID: 38336492
[TBL] [Abstract][Full Text] [Related]
6. Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients.
Haskin O; Ashkenazi-Hoffnung L; Ziv N; Borovitz Y; Dagan A; Levi S; Koren G; Hamdani G; Levi-Erez D; Landau D; Alfandary H
Transplantation; 2021 Nov; 105(11):e226-e233. PubMed ID: 34381004
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
Herishanu Y; Rahav G; Levi S; Braester A; Itchaki G; Bairey O; Dally N; Shvidel L; Ziv-Baran T; Polliack A; Tadmor T; Benjamini O;
Blood; 2022 Feb; 139(5):678-685. PubMed ID: 34861036
[TBL] [Abstract][Full Text] [Related]
8. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.
Malard F; Gaugler B; Gozlan J; Bouquet L; Fofana D; Siblany L; Eshagh D; Adotevi O; Laheurte C; Ricard L; Dulery R; Stocker N; van de Wyngaert Z; Genthon A; Banet A; Memoli M; Ikhlef S; Sestilli S; Vekhof A; Brissot E; Marjanovic Z; Chantran Y; Cuervo N; Ballot E; Morand-Joubert L; Mohty M
Blood Cancer J; 2021 Aug; 11(8):142. PubMed ID: 34376633
[TBL] [Abstract][Full Text] [Related]
9. Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia.
Parry H; McIlroy G; Bruton R; Damery S; Tyson G; Logan N; Davis C; Willett B; Zuo J; Ali M; Kaur M; Stephens C; Brant D; Otter A; McSkeane T; Rolfe H; Faustini S; Richter A; Lee S; Wandroo F; Shafeek S; Pratt G; Paneesha S; Moss P
J Hematol Oncol; 2022 Jan; 15(1):3. PubMed ID: 35000597
[TBL] [Abstract][Full Text] [Related]
10. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
[TBL] [Abstract][Full Text] [Related]
12. Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.
Gurion R; Rozovski U; Itchaki G; Gafter-Gvili A; Leibovitch C; Raanani P; Ben-Zvi H; Szwarcwort M; Taylor-Abigadol M; Dann EJ; Horesh N; Inbar T; Tzoran I; Lavi N; Fineman R; Ringelstein-Harlev S; Horowitz NA
Haematologica; 2022 Mar; 107(3):715-720. PubMed ID: 34320790
[TBL] [Abstract][Full Text] [Related]
13. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
Front Immunol; 2021; 12():752233. PubMed ID: 34899701
[TBL] [Abstract][Full Text] [Related]
14. The dynamics of quantitative SARS-CoV-2 antispike IgG response to BNT162b2 vaccination.
Kaneko S; Kurosaki M; Sugiyama T; Takahashi Y; Yamaguchi Y; Nagasawa M; Izumi N
J Med Virol; 2021 Dec; 93(12):6813-6817. PubMed ID: 34314037
[TBL] [Abstract][Full Text] [Related]
15. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
[TBL] [Abstract][Full Text] [Related]
16. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M; Suffiotti M; Pellaton C; Bouchaab H; Cairoli A; Salvadé V; Stevenel C; Hottinger R; Pythoud C; Coutechier L; Molinari L; Trono D; Ribi C; Gottardo R; Fenwick C; Pascual M; Duchosal MA; Peters S; Pantaleo G
JAMA Oncol; 2022 May; 8(5):e220446. PubMed ID: 35271706
[TBL] [Abstract][Full Text] [Related]
17. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
Guven DC; Sahin TK; Akın S; Uckun FM
Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D
Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148
[TBL] [Abstract][Full Text] [Related]
19. The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients.
Saiag E; Grupper A; Avivi I; Elkayam O; Ram R; Herishanu Y; Cohen Y; Perry C; Furer V; Katchman H; Rabinowich L; Ben-Yehoyada M; Halperin T; Baruch R; Goldshmidt H; Hagin D; Ben-Ami R; Sprecher E; Bomze D
Clin Microbiol Infect; 2022 May; 28(5):735.e5-735.e8. PubMed ID: 35183747
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccines for patients with haematological conditions.
Sun C; Pleyer C; Wiestner A
Lancet Haematol; 2021 May; 8(5):e312-e314. PubMed ID: 33811822
[No Abstract] [Full Text] [Related]
[Next] [New Search]